Arrowhead Pharmaceuticals (ARWR, Financial) has announced the impending retirement of its longstanding CFO, Ken Myszkowski, effective May 13. Myszkowski has been a pivotal figure in the company's financial operations since 2009. His departure does not stem from any disagreements within the company, according to official statements.
To ensure a smooth transition, Myszkowski will continue as an employee adviser, offering transition services to his successor until January 31, 2026. This move aims to maintain continuity and support as the company advances its strategic initiatives.
Arrowhead has appointed Daniel Apel as the new CFO. Apel brings a wealth of experience from his previous role as the global head of financial planning and analysis at Walgreens Boots Alliance (WBA) from 2019 to 2024. His expertise is expected to further strengthen Arrowhead's financial leadership.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Arrowhead Pharmaceuticals Inc (ARWR, Financial) is $44.54 with a high estimate of $80.00 and a low estimate of $21.00. The average target implies an upside of 246.06% from the current price of $12.87. More detailed estimate data can be found on the Arrowhead Pharmaceuticals Inc (ARWR) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Arrowhead Pharmaceuticals Inc's (ARWR, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Arrowhead Pharmaceuticals Inc (ARWR, Financial) in one year is $26.27, suggesting a upside of 104.12% from the current price of $12.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Arrowhead Pharmaceuticals Inc (ARWR) Summary page.
